Array Biopharma Inc.

Mirati Therapeutics, Inc.

Dean Russell Kahn

James F Blake

Li Ren

David A Moreno

Andrew T Metcalf

Spencer Phillip Pajk

Donghua Dai

Brett Joseph Prigaro

Yutong Jiang

Julia Haas

Qian Zhao

Gabrielle R Kolakowski

Shelley Allen

Mark Joseph Chicarelli

Adam Wade Cook

Tony P Tang

John Joseph Gaudino

Ellen Ruth Laird

Christopher Ronald Smith

John Peter Fischer

Matthew Arnold Marx

Martha E Rodriguez

John David Lawson

Jay Bradford Fell

Xiaolun Wang

John Michael Ketcham

James Gail Christensen

Aaron Craig Burns

Brad Newhouse

Erik James Hicken

Shane M Walls

Macedonio J Mejia

Bradley Jon Newhouse

Ginelle A Ramann

Pavel Savechenkov

Joshua Ryan Dahlke

Patrick Michael Barbour

Eugene Tarlton

Jacob Matthew O'Leary

Katie Keaton Brown

Michael Christopher Hilton

Phong Nguyen

Elizabeth A McFaddin

Guy P A Vigers

Elizabeth A Mcfaddin

Guy Pa Vigers

Megan L Mckenney

Hailong Zhang

Provided herein are compounds of the Formula (I): (I) and tautomers, stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein R, R, W, X, Y, Z, Ring A and (AA) have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Fused heterocyclic compounds as RET kinase inhibitors

Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

KRas G12D inhibitors

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X, R, R, R, R, Rand Rare as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Compounds for the treatment of BRAF-associated diseases and disorders

Provided herein are compounds of the Formula I: and tautomers and pharmaceutically acceptable salts and solvates thereof, wherein R, Rand Rhave the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. 

Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors

Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Boulder, CO, United States of America

Dean Russell Kahn